Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Authors not listed
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc · 2014
Abstract
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2014). A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia. <em>Chase Pharmaceuticals Corporation, an affiliate of Allergan plc</em>. https://clinicaltrials.gov/study/NCT02185053
Vancouver
Anonymous. A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia. Chase Pharmaceuticals Corporation, an affiliate of Allergan plc. 2014.
BibTeX
@misc{anon2014APhase,
title = {A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia},
author = {Anonymous},
journal = {Chase Pharmaceuticals Corporation, an affiliate of Allergan plc},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
IGC Pharma, LLC 2021
Open access · US-GOV
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
Vigil Neuroscience, Inc. 2023
Open access · US-GOV
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Kyowa Kirin Co., Ltd. 2017
Open access · US-GOV
A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
Neurotrope Bioscience, Inc. 2020
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Denali Therapeutics Inc. 2026
Open access · US-GOV
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Treeway B.V. 2023
Open access · US-GOV